期刊
LUNG CANCER
卷 155, 期 -, 页码 68-77出版社
ELSEVIER IRELAND LTD
DOI: 10.1016/j.lungcan.2021.03.005
关键词
Brigatinib; Anaplastic lymphoma kinase; Carcinoma; Non-small-cell lung; Quality of life; First-line therapy
资金
- ARIAD Pharmaceuticals, Inc.
In ALTA-1 L study, first-line brigatinib significantly prolonged progression-free survival in ALK+ NSCLC patients compared to crizotinib, and also demonstrated better health-related quality of life outcomes, with longer duration of improvement and improvement in functional and symptom scores.
Objective: In ALTA-1 L, first-line brigatinib versus crizotinib significantly prolonged progression-free survival in advanced ALK-positive (ALK+) non?small cell lung cancer (NSCLC). We report health-related quality of life (HRQOL) outcomes from ALTA-1 L. Materials and Methods: HRQOL was assessed using European Organization for Research and Treatment of Cancer Quality of Life Questionnaire?Core 30 (EORTC QLQ-C30) and lung cancer?specific module (QLQ-LC13). HRQOL time to worsening, change from baseline, and duration of improvement were analyzed. Results: EORTC QLQ-C30 and QLQ-LC13 compliance was >90 % for both groups (n = 131 each). Brigatinib versus crizotinib significantly delayed time to worsening in the EORTC QLQ-C30 global health status (GHS)/QOL (median: 26.74 vs 8.31 months; hazard ratio [HR]: 0.70; 95 % CI: 0.49, 1.00; log-rank P = 0.0485); emotional functioning, social functioning, fatigue, nausea and vomiting, appetite loss, and constipation scales (log-rank P < 0.05); delays in time to worsening for the physical, role, and cognitive functioning scales were not statistically significant. Mean change from baseline showed greater improvement in GHS/QOL and most EORTC QLQ-C30 functional and symptom scales with brigatinib versus crizotinib. Among patients with GHS/QOL improvement, brigatinib had longer duration of improvement versus crizotinib (median: not reached vs 11.99 months); similar results were seen in the physical, role, emotional, and social functioning; fatigue; nausea and vomiting; and appetite loss scales. Median time to worsening in dyspnea (QLQ-LC13) was 23.98 versus 8.25 months (brigatinib vs crizotinib; HR: 0.64; 95 % CI: 0.39, 1.05). Conclusion: Brigatinib significantly delayed time to worsening and prolonged duration of improvement in GHS/ QOL versus crizotinib, supported by improvement in functional and symptom scores. These preliminary analyses suggest brigatinib is the first ALK inhibitor with better HRQOL versus another ALK inhibitor in ALK inhib-itor-naive advanced ALK + NSCLC.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据